References
- Hurst RE. Bexarotene ligand pharmaceuticals. Curr Opin Investig Drugs. 2000;1(4):514–523.
- Panchal MR, Scarisbrick JJ. The utility of bexarotene in mycosis fungoides and sézary syndrome. Onco Targets Ther. 2015;8:367–373.
- Geskin L, Malone DC. An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma. J Dermatolog Treat. 2018;29(5):522–530.
- Centers for Medicare and Medicaid Services. Medicare provider utilization and payment data: part D prescriber; 2021 [cited 2021 May 8]. https://www.cms.gov/Research-Statistics-Data-and-Systems/StatisticsTrends-and-Reports/Medicare-Provider-Charge-Data/Part-D-Prescriber.
- ThePharmaLetter. Valeant pharma buys US rights to Eisai's Targretin for $65 million upfront; 2021 [cited 2021 May 16]. https://www.thepharmaletter.com/article/valeant-pharma-buys-us-rights-to-eisai-s-targretin-for-65-million-upfront.
- Rosenberg ME, Rosenberg SP. Changes in retail prices of prescription dermatologic drugs from 2009 to 2015. JAMA Dermatol. 2016;152(2):158–163.